Nupsala Launches Pioneering Intibio A2MG Kit
3 months ago 
283 views
Nupsala has launched its pioneering Intibio A2MG (Alpha-2-Macroglobulin) processing kit, an innovative advanced processing kit that utilises a filtration system to isolate A2MG from horse plasma, removing destructive inflammatory proteins while retaining beneficial proteins and growth factors which can slow down the progression of osteoarthritis (OA) and damage to cartilage.
Developed by Intibio, a leading Belgian biologicals company, the innovative kit provides equine vets with a valuable new evidence-based orthobiologic option for A2MG processing based on a patented technology using unique filters. This results in the highest A2MG levels (and volume), total protein amounts and growth factor levels in comparison to commercially available alternatives. The kit, which can be used with existing centrifuge systems, is available in 15ml or 30ml pack sizes. It is easy to use and contains all the necessary elements – including anticoagulant - to reduce hassle for vets. The harvested A2MG can be stored frozen for up to 12 months, providing flexibility for vet practices.
To further support vets, Nupsala also offers its own StrideSpin™ centrifuge system. While it works seamlessly with the IntiBio A2MG kit and other A2MG products, StrideSpin™ is purpose-built for all veterinary applications. It supports a wide range of biological products and is designed to adapt to future needs – from advanced orthobiologics to semen processing and haematocrit – giving practices a complete, future-ready solution.
Professor Jan H Spaas, CEO of Intibio, comments: “We are excited to announce our strategic partnership with Nupsala to bring our novel orthobiologics kit to vets in the UK. This collaboration marks a significant milestone in our mission to advance veterinary care by expanding access to innovative, evidence-based solutions. The partnership combines our cutting-edge orthobiologics technology with Nupsala’s scientific approach, deep market knowledge and established distribution network, ensuring that vets are equipped with high-quality tools to support patient outcomes. We look forward to a successful collaboration that drives innovation, improves care, and supports the growing demand for biologically driven orthopaedic therapies.”
Greg McGarrell, CEO of Nupsala, adds: “At Nupsala, we are committed to supporting innovation that genuinely advances equine health. Our new collaboration with Intibio reflects this commitment and brings together the shared expertise, integrity, and forward-thinking approach of both companies. The Intibio A2MG processing kit represents the next evolutionary step in equine orthobiological therapies, offering vets a high-quality, accessible solution grounded in science. We’re proud to partner with a company that values collaboration as much as we do, and we look forward to what this means for the future of equine care.”
To support the launch of the Intibio A2MG processing kit, Nupsala is offering vets the opportunity to win a fantastic De’Longhi coffee machine worth £300 and 10 Nupsala branded mugs. Vet practices that order either a 15ml or 30ml Intibio A2MG kit before the end of October will automatically be entered into the prize draw.
For further information on the Intibio A2MG processing kit go to www.nupsala.com or contact [email protected].
More from Nupsala
4 days ago